ROS1 gene rearrangement is identified in NSCLC.
MAJOR FINDING: ROS1 chromosomal rearrangements define a molecular subtype of NSCLC. ROS1 rearrangements tend to occur in younger, non-smoking NSCLC patients. ROS1-positive NSCLC patients may benefit from crizotinib therapy.